biostudies-literatureRuppert AMRocheNovartis, FranceInstitut National Du Cancer, FranceAstraZeneca100052https://www.ebi.ac.uk/biostudies/studies/S-EPMC8474404biostudies-literatureUnknown1(3)<h4>Introduction</h4><i>KRAS</i> mutations are detected in 20% to 30% of NSCLC. However, <i>KRAS</i> mutation subtypes may differently influence the outcome of patients with advanced NSCLC.<h4>Methods</h4>In the Biomarkers France study, 4894 <i>KRAS</i> mutations (26.2%) were detected in 4634 patients from the 17,664 enrolled patients with NSCLC. Survival and treatment data on noncurative stage III to IV NSCLC were available for 901 patients. First- and second-line treatment effects on progression-free survival and overall survival were analyzed according to the <i>KRAS</i> mutations subtype.<h4>Results</h4>Over 95% of patients with <i>KRAS</i> mutation were smokers or former smokers who were white (99.5%), presenting with adenocarcinoma (82.5%). The most common <i>KRAS</i> mutation subtypJTO clinical and research reportsOutcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancerologie Thoracique Biomarkers France Study by <i>KRAS</i> Mutation Subtypes.PMC84744042011-038Bringuier PPDebieuvre DFoucher PJanicot HBarlesi FWesteel VRicordel CPoudenx MEscande FBeau-Faller MOuafik LRouquette ILemoine AMerlio JPRuppert AMMazieres JMonnet IMorin FLanglais ASouquet PJWislez MfalseOutcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancerologie Thoracique Biomarkers France Study by <i>KRAS</i> Mutation Subtypes.<h4>Introduction</h4><i>KRAS</i> mutations are detected in 20% to 30% of NSCLC. However, <i>KRAS</i> mutation subtypes may differently influence the outcome of patients with advanced NSCLC.<h4>Methods</h4>In the Biomarkers France study, 4894 <i>KRAS</i> mutations (26.2%) were detected in 4634 patients from the 17,664 enrolled patients with NSCLC. Survival and treatment data on noncurative stage III to IV NSCLC were available for 901 patients. First- and second-line treatment effects on progression-free survival and overall survival were analyzed according to the <i>KRAS</i> mutations subtype.<h4>Results</h4>Over 95% of patients with <i>KRAS</i> mutation were smokers or former smokers who were white (99.5%), presenting with adenocarcinoma (82.5%). The most common <i>KRAS</i> mutation subtyp2020-01-01T00:00:00Z2020 Sep2025-06-01T00:32:05.837Z2025-06-01T00:32:05.837ZS-EPMC84744043458994710.1016/j.jtocrr.2020.100052